Inhibitory effect of ethanol extract of Piper longum L. on rabbit platelet aggregation through antagonizing thromboxane A2 receptor

被引:16
作者
Iwashita, Masaya
Saito, Masaki
Yamaguchi, Yasunaga
Takagaki, Ryoji
Nakahata, Norimichi
机构
[1] Tohoku Univ, Grad Sch Pharmaceut Sci, Dept Cellular Signaling, Aoba Ku, Sendai, Miyagi 9808578, Japan
[2] Tohoku Univ, 21st Century COE Program CRESCENDO, Aoba Ku, Sendai, Miyagi 9808578, Japan
[3] Maruzen Pharmaceut Co Ltd, Res Ctr, Hiroshima 7293102, Japan
关键词
Piper longum L; platelet aggregation; thromboxane A(2) receptor;
D O I
10.1248/bpb.30.1221
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Piper longum L. has been used as a crude drug for the treatment of disorders of poor peripheral blood circulation in Asia. However, the detailed mechanism of its action has not been clarified as yet. In the present study, we examined the effects of several extracts of Piper longum L. on rabbit platelet function. Thromboxane A 2 receptor agonist U46619 caused rabbit platelet aggregation, which was potently inhibited by the ethanol or butanol extract of Piper longum L. The ethanol extract inhibited U46619-induced platelet aggregation in a concentration-dependent manner, but only weakly inhibited that induced by thrombin. The maximum response to U46619 was reduced by 100% ethanol extract concentration dependently, suggesting that the inhibitory mode of U46619-induced platelet aggregation by the ethanol extract was non-competitive. The extract also inhibited U46619-induced phosphoinositide hydrolysis with a similar concentration dependency to the platelet aggregation. Furthermore, the extract inhibited binding of [H-3]SQ29548 to thromboxane A(2) receptor in intact platelets in a concentration-dependent manner. These results suggest that Piper longum L. contains a constituent(s) that inhibits platelet aggregation as a non-competitive thromboxane A2 receptor antagonist.
引用
收藏
页码:1221 / 1225
页数:5
相关论文
共 23 条
[1]  
Aronow WS, 2004, J GERONTOL A-BIOL, V59, P172
[2]  
BUCHANAN GR, 1977, AM J CLIN PATHOL, V68, P355
[3]   Identification of Gα13 as one of the G-proteins that couple to human platelet thromboxane A2 receptors [J].
Djellas, Y ;
Manganello, JM ;
Antonakis, K ;
Le Breton, GC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (20) :14325-14330
[4]   Differential requirements for calcium and Src family kinases in platelet GPIIb/IIIa activation and thromboxane generation downstream of different G-protein pathways [J].
Dorsam, RT ;
Kim, S ;
Murugappan, S ;
Rachoor, S ;
Shankar, H ;
Jin, JG ;
Kunapuli, SP .
BLOOD, 2005, 105 (07) :2749-2756
[5]   PHARMACOLOGICAL STUDIES ON THE TXA2 SYNTHETASE INHIBITOR (E)-3-[P-(1H-IMIDAZOL-1-YLMETHYL)PHENYL]-2-PROPENOIC ACID (OKY-046) [J].
HIRAKU, S ;
TANIGUCHI, K ;
WAKITANI, K ;
OMAWARI, N ;
KIRA, H ;
MIYAMOTO, T ;
OKEGAWA, T ;
KAWASAKI, A ;
UJIIE, A .
JAPANESE JOURNAL OF PHARMACOLOGY, 1986, 41 (03) :393-401
[6]   Cell signalling through thromboxane A2 receptors [J].
Huang, JS ;
Ramamurthy, SK ;
Lin, X ;
Le Breton, GC .
CELLULAR SIGNALLING, 2004, 16 (05) :521-533
[7]   ANTAGONISTIC ACTION OF AA-2414 ON THROMBOXANE-A2 PROSTAGLANDIN ENDOPEROXIDE RECEPTOR IN PLATELETS AND BLOOD-VESSELS [J].
IMURA, Y ;
TERASHITA, Z ;
SHIBOUTA, Y ;
INADA, Y ;
NISHIKAWA, K .
JAPANESE JOURNAL OF PHARMACOLOGY, 1990, 52 (01) :35-43
[8]   Antiplatelet activity of J78 (2-chloro-3-[2′-bromo, 4′-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone),an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization [J].
Jin, YR ;
Cho, MR ;
Ryu, CK ;
Chung, JH ;
Yuk, DY ;
Hong, JT ;
Lee, KS ;
Lee, JJ ;
Lee, MY ;
Lim, Y ;
Yun, YP .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (01) :214-219
[9]   Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets [J].
Klages, B ;
Brandt, U ;
Simon, MI ;
Schultz, G ;
Offermanns, S .
JOURNAL OF CELL BIOLOGY, 1999, 144 (04) :745-754
[10]   Platelets and anti-platelet therapy [J].
McNicol, A ;
Israels, SJ .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2003, 93 (04) :381-396